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SUMMARY
Glucagon-like peptide 1 (GLP-1) is a hormone
released from enteroendocrine L cells. Although first
described as a glucoregulatory incretin hormone,
GLP-1 also suppresses inflammation and promotes
mucosal integrity. Here, we demonstrate that plasma
GLP-1 levels are rapidly increased by lipopolysac-
charide (LPS) administration in mice via a Toll-like
receptor 4 (TLR4)-dependent mechanism. Experi-
mental manipulation of gut barrier integrity after
dextran sodium sulfate treatment, or via ischemia/re-
perfusion experiments in mice, triggered a rapid rise
in circulating GLP-1. This phenomenonwas detected
prior to measurable changes in inflammatory status
and plasma cytokine and LPS levels. In human
subjects, LPS administration also induced GLP-1
secretion. Furthermore, GLP-1 levels were rapidly
increased following the induction of ischemia in the
human intestine. These findings expand traditional
concepts of enteroendocrine L cell biology to
encompass the sensing of inflammatory stimuli and
compromised mucosal integrity, linking glucagon-
like peptide secretion to gut inflammation.
INTRODUCTION
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendo-
crine cells (EECs) and was originally described as an incretin
hormone, which also exerts other metabolic actions such
as reduction in appetite and food intake (Holst, 2007).
These actions supported the development of GLP-1 receptor
(GLP-1R) agonists for the treatment of type 2 diabetes.
GLP-1 acts through a single receptor widely expressed in
multiple tissues, suggesting that it could have additional roles
beyond glucose lowering. Notably, GLP-1R agonists exert
beneficial effects in experimental preclinical models of inflam-
matory disease (Lee and Jun, 2016). However, the mechanisms
through which incretin therapies control inflammation remain
incompletely understood (Drucker, 2016).
The gastrointestinal tract, the site of endogenous GLP-1
production, is colonized by billions of bacteria, some of which
produce pro-inflammatory lipopolysaccharides (LPS), which
influence gut immunity (Gnauck et al., 2016) and hormone
release (Bogunovic et al., 2007). LPS act mainly through the
activation of Toll-like receptor 4 (TLR4) (Poltorak et al., 1998).
Under normal conditions, several mechanisms restrict LPS
within the gut lumen; however, in some situations, especially
when intestinal barrier function is compromised, LPS molecules
enter the blood circulation and trigger systemic inflammation.
Intriguingly, LPS or interleukin-6 (IL-6) increased plasma GLP-1
levels in mice, through incompletely understood mechanisms
(Ellingsgaard et al., 2011; Kahles et al., 2014; Nguyen et al.,
2014).
Here we show that LPS increase GLP-1 secretion through a
TLR4-dependent mechanism. In mice, experimental alteration
of the gut barrier led to a rapid rise in plasma GLP-1
levels through mechanisms enabling luminal LPS to access
EECs. Remarkably, LPS also stimulated GLP-1 secretion in
humans, and GLP-1 levels were rapidly increased in humans
with acute experimental intestinal ischemia. Hence, gut barrier
alteration facilitates LPS exposure, which in turn augments
GLP-1 secretion from local L cells. These findings redefine
classical nutrient-stimulated concepts of GLP-1 acting as an
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incretin hormone to include a role for GLP-1-producing L cells
as sensors of local inflammation and barrier integrity.
RESULTS
LPS Induce the Expression and Secretion of GLP-1
The actions of LPS to increase circulating GLP-1 (Nguyen et al.,
2014) may be mediated by (1) the enhancement of its secretion
and/or (2) the inhibition of its degradation. To distinguish
between these mechanisms, we investigated the effects of
LPS on GLP-1 metabolism in vivo. Mice injected with LPS
exhibited marked increases in plasma levels of LPS, measured
as 3-hydroxymyristate (3-HM) fatty acids (Figure 1A). Intestinal
mRNA transcripts encoding pro- and anti-inflammatory cyto-
kines and TLR4 peaked 3 hr after LPS injection (Figures 1B
and 1C), and levels of circulating cytokines increased rapidly
(Figure 1D). Ileal expression of proglucagon (Gcg, which
encodes GLP-1) and prohormone convertase 1/3 (Pcsk1) was
rapidly and transiently induced (Figures 1E and 1F). As shown
in Figures 1G and 1H, both active and total forms of GLP-1
were induced by LPS injection. Due to ethical concerns and in
agreement with the Animal Research: Reporting of In Vivo
Experiments (ARRIVE) guidelines and reduce, replace, and refine
(3R) principles, limited analysis at t = 3 and 6 hr revealed that
saline administration had no effect compared to LPS injection
(Figure 1I). Furthermore, positive correlations between total
GLP-1 and LPS were observed (Figure 1J).
We next determined whether intraluminal LPS could stimulate
L cell GLP-1 secretion. Both intraluminal glucose and LPS stim-
ulated GLP-1 secretion from mouse ileum explants (Figure 1K).
Furthermore, GLP-1 secretion was modestly but rapidly
increased after direct LPS stimulation of GLUTag (Figures 1L
and 1M) and STC-1 EECs (Figure 1N). Ex vivo, quantification of
intestinal fatty acid-binding protein (I-FABP), a marker of intesti-
nal cell membrane integrity (Pelsers et al., 2005), did not show
any differences with the highest concentration of LPS. In vitro,
cytotoxicity tests revealed no adverse effects of LPS on the
integrity of these two cell lines (data not shown).
LPS InduceGLP-1 Secretion through a TLR4-Dependent
Pathway
Although IL-6 has been proposed as the mediator of LPS-
induced GLP-1 secretion (Kahles et al., 2014), injection of LPS
in IL-6-deficient (Il6/) mice (Figure S1A) led to an attenuated
but detectable increase in GLP-1 secretion (Figure S1B).
Furthermore, LPS did not induce GIP secretion (Figure S1C),
making indirect GLP-1 secretion through GIP unlikely. We next
blocked muscarinic neural transmission with atropine, which
resulted in substantially attenuated basal GLP-1 secretion. In
contrast, atropine did not abrogate the stimulatory effect of
LPS on GLP-1 secretion (Figure S1D).
Although TLR4 has been considered the classical receptor
transducing an inflammatory response to LPS, recent data impli-
cate caspases as a non-canonical inflammasome activation
pathway that senses LPS (Hagar et al., 2013). After LPS injection,
plasma levels of pro- and anti-inflammatory cytokines were
robustly increased in wild-type (WT), but not in TLR4-deficient
(Tlr4/) mice (Figure 2A); however, the rise in plasma GLP-1
levels was extinguished (Figure 2B), consistent with a critical
role for TLR4 in coupling LPS to GLP-1 secretion. As TLR4 is
expressed by intestinal EECs (Bogunovic et al., 2007), we next
assessed the TLR4 pathway in GLUTag and STC-1 cell lines.
GLP-1 secretion was abolished when GLUTag (Figure 2C) or
STC-1 cells (Figure 2D) were challenged with LPS in the pres-
ence of a TLR4 antagonist, TAK-242 (Figures 2C and 2D). This
correlated with an elevation of calcium monitored in single cells
in response to LPS in both cell lines (Figures S2A and S2B).
Incubation in calcium-free buffer totally blunted this increase,
highlighting the importance of extracellular calcium (Figure S2B).
Furthermore, LPS-induced calcium fluxes were blocked by a
TLR4 antagonist (Figure S2C). Hence, LPS require TLR4 to
induce intracellular calcium flux and GLP-1 secretion in vitro.
Luminal LPS Enhance GLP-1 Secretion after Gut
Barrier Injury
LPS administered intravenously (i.v.) or intraperitoneally (i.p.)
induced GLP-1 secretion, whereas no effect was observed
when LPS were given through an oral gavage (Table S1). These
findings imply that LPS may need to reach gut EECs at their
basolateral location via the circulation or through luminal expo-
sure in the presence of an altered gut barrier. We next examined
animal models in which gut barrier function was compromised.
We first studied dextran sodium sulfate (DSS)-induced colitis.
As shown in Figure 3A, endotoxemia after an oral administration
of LPS in control animals was unchanged over the 6-hr period,
yet it increased in DSS-treated mice. Furthermore, plasma
GLP-1 levels were increased in DSS-treated mice upon LPS
gavage, whereas no increase in GLP-1 was observed in control
animals (Figure 3B). Circulating LPS and GLP-1 levels were posi-
tively correlated (Figure 3C). Independent of DSS treatment, the
oral administration of LPS also led to a marked but transient
increase in IL-6 (Figure 3D).
To further assess whether alteration of the gut barrier could
facilitate GLP-1 secretion through exposure to endogenous
luminal bacterial-derived LPS, we studied mice with mesenteric
ischemia/reperfusion (I/R) injury. Gut ultrastructure was highly
disorganized after I/R. Short times of I/R were sufficient to dam-
age intestinal villi (Figures S3A and S3B), with further gut injury
evident following longer periods of I/R (Figure S3C). Increased
GLP-1 levels were observed after a 15-min ischemia/15-min
reperfusion period, and they continued to rise after 20-min
ischemia/120-min reperfusion (Figure 3E). Levels of Il6 and Il10
mRNA transcripts were significantly increased with longer times
of reperfusion (Figure 3F). Circulating levels of these two cyto-
kines were detectable after 20 min of ischemia and rose with
increased reperfusion time (Figure 3G).We next compared levels
of GLP-1 and I-FABP. Only GLP-1 levels rose significantly after a
short reperfusion time, suggesting that marked epithelial injury is
not required for triggering GLP-1 secretion (Figure 3H), whereas
plasma levels of LPS, indirectly quantified as 3-HM, were
unchanged during the 2 hr of reperfusion (Figure 3I).
To further investigate the role of endogenous luminal LPS, we
used two pharmacological approaches to (1) decrease the quan-
tity of active LPS or (2) decrease signaling through the TLR4
receptor. First, we treated mice with Polymyxin B, an antibiotic
that binds to and prevents the activity of LPS. In Polymyxin
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Figure 1. LPS Enhance GLP-1 Secretion
(A) Plasma 3-HM quantification after LPS i.p. injection in mice (n = 9–10).
(B and C) Ileum cytokines (B) and Tlr4 (C) mRNA relative expression after LPS i.p. injection in mice (n = 9–10).
(D) Cytokine plasma levels after LPS i.p. injection in mice (n = 8).
(E and F) Mouse ileum Gcg (E) and Pcsk1 (F) mRNA relative expression after LPS i.p. injection (n = 9–10).
(G–I) Plasma active GLP-1 (G) and plasma total GLP-1 (H and I) after LPS i.p. injection in mice (LPS injection, n = 9–10; and saline injection, n = 5).
(J) Correlation between plasma 3-HM and total GLP-1.
(K) GLP-1 secreted by mouse ileum explants challenged by glucose or LPS for 1 hr (n = 11–16).
(L) GLP-1 secreted by GLUTag cells after 90 min of glucose or LPS stimulation (n = 6).
(M) Time course of GLP-1 secretion by GLUTag cells after LPS stimulation (n = 4–5).
(N) GLP-1 secreted by STC-1 cells after 90 min of LPS stimulation (n = 4–5).
All results are expressed as mean ± SEM.
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B-treated mice subjected to I/R, the induction of GLP-1 secre-
tion was blunted (Figures 3J and 3K). The induction of IL-10
was also slightly reduced (Figure 3L). Second, pretreatment of
mice with a TLR4 antagonist attenuated the I/R-induced
increase in GLP-1 levels (Figure 3M), associated with a lower
GLP-1 secretion index (Figure 3N) and reduced levels of IL-10
(Figure 3O). These results suggest that endogenous luminal
LPS induce GLP-1 secretion when gut barrier function is
compromised. As intestinal GLP-2 is known to be co-secreted
with GLP-1, we tested whether GLP-2 was also increased by
LPS or gut injury. Figure S4 shows that LPS injection (Figure S4A)
and I/R experiments (Figure S4B) both led to a significant
increase in plasma GLP-2 levels.
LPS-Induced GLP-1 Secretion Is Detected in Humans
As shown in Figure 4A, plasma GLP-1 levels were increased 3 hr
after LPS, but not saline, injection in human subjects. LPS also
induced a transient increase in pro- and anti-inflammatory cyto-
kines (Figure 4B). Finally, we utilized a model of I/R (Grootjans
et al., 2010) to evaluate whether I/R injury in the human gut in vivo
was associated with an increase in GLP-1 secretion. Arteriove-
nous differences in plasma GLP-1 levels were measured before,
after 45 min of ischemia, and after 30 or 120 min of reperfusion.
GLP-1 levels were markedly increased after 45 min of ischemia,
and they returned to baseline levels after reperfusion of human
intestine (Figure 4C). These results demonstrate that even brief
periods of human gut injury are associated with a rapid induction
of GLP-1 secretion in vivo.
DISCUSSION
We and others have previously shown that LPS increase
plasma levels of GLP-1 in mice (Kahles et al., 2014; Nguyen
et al., 2014). Our current study implies that increased secretion
A
B C D
Figure 2. LPS Induce GLP-1 Secretion
through a TLR4-Dependent Mechanism
(A and B) Cytokine (A) and total GLP-1 (B) plasma
levels 3 hr after LPS i.p. injection inWT and Tlr4/
mice (n = 10).
(C) GLP-1 secretion by GLUTag cells after LPS
stimulation (200 ng/mL) for 90 min ± TLR4
antagonist (n = 4–6).
(D) GLP-1 secretion of STC-1 cells after LPS
stimulation (10 ng/mL)± TLR4 antagonist (n = 4–6).
All results are expressed asmean ± SEM. See also
Figures S1 and S2.
is the likely mechanism accounting for
the rise in GLP-1 levels following LPS
administration. Tlr4/ mice and EECs
treated with a TLR4 antagonist estab-
lished the canonical TLR4 pathway as a
key transducer of signals linking LPS to
the stimulation of GLP-1 secretion.More-
over, in Tlr4/ mice, plasma cytokines
are strongly reduced, consistent with
data linking IL-6 and tumor necrosis fac-
tor alpha (TNF-a) to the stimulation of GLP-1 secretion (Ellings-
gaard et al., 2011; Gagnon et al., 2015).
Under physiological conditions, LPS do not pass through the
gut barrier except in small quantities during nutrient ingestion
(Erridge et al., 2007). Indeed, as expected, oral administration
of purified LPSmolecules did not induce an increase in systemic
endotoxemia or GLP-1 secretion. However, when gut barrier
function was damaged, such as in ileum explants or in DSS-
treated mice, exogenous LPS administered into the lumen led
to a significant induction of GLP-1 secretion. In the DSS experi-
ment, the increased levels of IL-6 in both groups of mice (at
t = 1hr)might be explainedby the activation ofB1 cells of the lam-
ina propria (Murakami et al., 1994) and/or by the rapid sensing of
bacterial products by intestinal epithelial cells shown to secrete
pro-inflammatory cytokines (Kagnoff and Eckmann, 1997).
In pathophysiological situations exemplified by I/R injury, a
very rapid secretion of GLP-1 was observed, findings dependent
upon the bioavailability of active LPS. However, for longer time
periods of reperfusion, GLP-1 release could also be secondary
to cell lysis. Nevertheless, we cannot exclude the possibility
that additional molecules present in the gut lumenmight simulta-
neously stimulate GLP-1 secretion during gut injury. Notably,
under the defined experimental conditions studied herein, we
did not observe changes in circulating LPS or in LPS levels in
lymph nodes (data not shown). Nevertheless, LPS stimulated
GLP-1 secretion when injected into mice or humans. This
suggests that LPS could act through a TLR4 receptor located
on the basolateral membranes of EECs, consistent with previous
findings (Brighton et al., 2015; Vamadevan et al., 2010) and with
our observations linking experimental disruption of gut barrier
function with stimulation of GLP-1 secretion.
The LPS-enteroendocrine GLP-1 axis described here is
consistent with a putative role for EECs in the innate immune
response against pathogens, to maintain mucosal immune
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homeostasis (Bogunovic et al., 2007; Selleri et al., 2008). More-
over, EECs represent key orchestrators of immune responses
to pathogens and commensal bacteria (Worthington, 2015).
EECs localized within the mucosa without luminal access
may be more easily engaged by LPS molecules after mucosal
barrier degradation, as occurs upon I/R injury. The increase in
permeability associated with gut injury likely facilitates LPS
access to and stimulation of enteroendocrine L cells,
with resultant GLP-1 secretion. GLP-1 in turn may act as an
anti-inflammatory peptide that controls mucosal integrity and
attenuates both local and systemic inflammation (Drucker,
2016; Lee and Jun, 2016). Indeed, both Paneth cells (known
to produce antimicrobial components) and intestinal intraepi-
thelial lymphocytes have been reported to express a functional
GLP-1R (Kedees et al., 2013; Yusta et al., 2015), and loss of the
GLP-1R increases the severity of DSS-induced intestinal injury
(Yusta et al., 2015).
The physiological relevance of GLP-1 secretion in the control
of basal gut barrier homeostasis remains obscure. Nevertheless,
liraglutide, a GLP-1 analog, improved gut permeability in rats
(Nozu et al., 2017) and induced barrier protective effect by
improving Brunner’s gland function (Bang-Berthelsen et al.,
2016). In addition, GLP-1R agonists promoted intestinal growth
(Kissow et al., 2012; Simonsen et al., 2007) through fibroblast
growth factor 7 (Koehler et al., 2015), and exogenous GLP-1
protects the gut against oxidative damage (Deniz et al., 2015).
Whereas the contribution of endogenously secreted GLP-1 to
gut growth appears to be modest (Wismann et al., 2017), endog-
enous GLP-1 contributes to gut recovery in the pathophysiolog-
ical context of chemotherapy (Kissow et al., 2013). Thus, the
4.8-fold increase in GLP-1 secretion observed here could also
modulate gut homeostasis through local actions to restore gut
integrity. L cells also secrete GLP-2, whose role in promoting
gut barrier function is well established (Drucker and Yusta,
2014). GLP-2 reduces intestinal permeability throughmodulation
of gut barrier function (Cani et al., 2009;Moran et al., 2012), and it
exerts beneficial effects in the rat gastrointestinal tract after
intestinal I/R (Zhang et al., 2008). Beyond local gut effects, rising
GLP-1 levels during gut ischemia may exert protective effects on
heart (Drucker, 2016), kidney (Skov, 2014), lung (Viby et al.,
2013), and liver (Wang et al., 2014). Furthermore, central GLP-1
reduces inflammation-induced fever (Rinaman and Comer,
2000). Hence, GLP-1may act as an early signal to facilitate organ
protection following disruption of gut barrier function.
Previous studies have correlated increased levels of circu-
lating GLP-1 with the extent of concomitant critical illness in
human subjects (Ingels et al., 2017; Kahles et al., 2014; Lebherz
et al., 2017). Our current findings illuminate the importance of
GLP-1 in this context by demonstrating that (1) LPS acutely
induce GLP-1 secretion in humans and (2) the injured human
gut responds rapidly to ischemic injury with increased GLP-1
secretion. The prompt GLP-1 secretion after gut barrier injury
further highlights the role of the enteroendocrine L cell and
GLP-1 in the response to injury and inflammation, expanding
concepts of L cell function to include roles as both a nutrient
and pathogen sensor. Indeed, recent findings have questioned
the relative importance of gut versus pancreatic GLP-1 for the
control of glucose homeostasis (Chambers et al., 2017). Our
current data add to the body of evidence implicating GLP-1 as
a component of the mucosal response to external injury, and
they suggest that GLP-1 may represent a candidate early
biomarker of gut injury in humans. Indeed, in the present I/R
experiments, GLP-1 secretion occurs earlier than I-FABP, itself
a promising biomarker of gut injury (Khadaroo et al., 2014).
Further work will be needed to determine whether GLP-1 levels
reflect the severity of gastrointestinal damage in humans with
localized or extensive gastrointestinal injury. Collectively, our
data position the L cell as a key mucosal sensor of gut injury,
which responds to mucosal damage by secretion of the
glucagon-like peptides, which in turn could promote restoration
of mucosal integrity and attenuation of inflammation.
EXPERIMENTAL PROCEDURES
Animals
All animal procedures were in accordance with institutional guidelines and
approved by the University of Burgundy’s Ethics Committee on the Use of
Laboratory Animals (protocol number 5459). All experiments were performed
using male C57BL/6J mice (8–12 weeks old); Tlr4/ mice were provided by
Dr. Bernard Ryffel (Hoshino et al., 1999). Blood samples were collected in
EDTA-coated tubes. Plasma was separated by centrifugation at 7,200 3 g
for 10 min at 4C. Blood and plasma samples were stored at 20C.
Acute LPS Administration
LPS were i.p. injected at 1 mg/kg. Details are provided in the Supplemental
Experimental Procedures.
Gut Injury Models
DSS treatment was adapted from previously described experimental proced-
ures (Kitajima et al., 1999). The oral load of LPS (5 mg/animal) was performed
Figure 3. Gut Injury Induces GLP-1 Secretion in Mice
(A and B) Plasma 3-HM (A) and total GLP-1 (B) levels after LPS gavage in control and DSS-treated mice (n = 8–9).
(C) Plasma 3-HM and total GLP-1 correlation.
(D) IL-6 plasma levels after LPS gavage in control and DSS-treated mice (n = 8).
(E) Total GLP-1 plasma levels after mesenteric I/R (n = 5).
(F) Ileum cytokine mRNA relative expression after mesenteric I/R (n = 5).
(G) Cytokine plasma levels after 20 min of ischemia and 15, 60, or 120 min of reperfusion (n = 4–5).
(H) Total GLP-1 and I-FABP plasma levels after 20 min of ischemia and 15 or 120 min of reperfusion (n = 6).
(I) LPS blood levels after 20 min of ischemia and 15, 60, or 120 min of reperfusion (n = 5–6).
(J) Total GLP-1 plasma levels before and after I/R (20/15 min) in control and Polymyxin B-treated mice (n = 6).
(K and L) Fold induction of GLP-1 (K) and cytokine (L) plasma levels after I/R (20/15 min) in control and Polymyxin B-treated mice (n = 6).
(M) Total GLP-1 plasma levels before and after I/R (20/15 min) in control and TLR4 antagonist-treated mice (n = 6).
(N and O) Fold induction of GLP-1 (N) and cytokine (O) plasma levels after I/R in control and TLR4 antagonist-treated mice (n = 6).
All results are expressed as mean ± SEM. See also Table S1 and Figures S3 and S4.
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after DSS treatment (2.5% [w/v] for 7 days in drinking water). Intestinal I/R was
achieved through an occlusion of the superior mesenteric artery. Polymyxin B
(0.2 mg/mL for 14 days in drinking water) and TLR4 antagonist (i.p. injection
at 0.2 mg/animal) were administered prior to I/R experiments. Details are
provided in the Supplemental Experimental Procedures.
Real-Time qPCR
Details are provided in the Supplemental Experimental Procedures.
Human LPS Injection
Experimental endotoxemia was induced in healthy volunteers (men from 18
to 35 years old) through an i.v. administration of LPS at 2 ng/kg. Experiments
were in accordance with the Declaration of Helsinki. After approval from the
local ethics committee of the Radboud University Medical Center, volunteers
gave written informed consent to participate in the study. Subjects were
screened before participation and had a normal physical examination, electro-
cardiography, and routine laboratory values. Details are provided in the
Supplemental Experimental Procedures.
Human Intestinal I/R
The experimental protocol was performed as previously described (Grootjans
et al., 2010). Experiments were in accordance with the Declaration of Helsinki.
The study was approved by the Medical Ethics Committee of the Maastricht
University Medical Center, and written informed consent of all patients (six
patients with a median age of 67 years, range of 42–85 years) was obtained.
Details are provided in the Supplemental Experimental Procedures.
GLP-1 Secretion Experiments
Ex vivoGLP-1 secretion was studied in a mice model of ileum explants. In vitro
GLP-1 secretion was investigated using the murine enteroendocrine cell lines
A B
C
Figure 4. LPS and Intestinal I/R Lead to GLP-1 Secretion in Humans
(A and B) Total GLP-1 (A) and cytokine (B) plasma levels in LPS-injected and control subjects (n = 15).
(C) Total GLP-1 arteriovenous differences (V-A) in patients before and after 45 min of intestinal ischemia and 0, 30, or 120 min reperfusion (n = 6).
All results are expressed as mean ± SEM.
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GLUTag and STC-1. Details are provided in the Supplemental Experimental
Procedures.
Biochemical Analysis
LPS concentrations were measured through the quantification of 3-HM levels
according to the procedure previously described (Pais de Barros et al., 2015).
Active/total GLP-1 and I-FABP concentrations were determined by commer-
cially available ELISA Kits (EGLP-35K, Millipore; EZGLP1T-36K, Millipore;
E-EL-M0735, Elabscience) in accordance with the manufacturers’ protocols.
Cytokine plasma levels were measured by Milliplex MAP 5-Plex Kit using
mouse cytokine/chemokine magnetic bead panel (MCYTOMAG-70K,
Millipore), according to the manufacturer’s protocol, and using a LuminexR
apparatus (Bio-Plex 200, Bio-Rad).
Statistical Analysis
Data are presented asmean ± SEM. Statistical analyses were performed using
Prism (GraphPad). To decide whether to use parametric or non-parametric
statistics, the normality of distributions was assessed with the Shapiro-Wilk
test (under n = 7, distributions were considered to be non-normal). Statistical
significance of differences between two groups was evaluated with the Mann-
Withney U test or the Sudent’s t test (a statistical correction was applied when
variances were different between groups). For more than two groups, Kruskal-
Wallis with Dunn’s post hoc test or one-way ANOVA with Dunnett’s post hoc
test was performed. Spearman correlations were calculated between groups.
A value of p < 0.05 was considered statistically significant (NS, not significant;
*p < 0.05, **p < 0.01, and ***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.10.008.
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